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of schizophrenia who were continuously enrolled with pharmacy coverage for 
12-months before treatment initiation. Patients with a diagnosis of bipolar, 
epilepsy or migraine were excluded. The AP cohort was identified by the first 
prescription fill with no prior use in previous 12-months. The combination 
therapy cohort (V+AP) was identified by the first prescription fill for V and an AP 
fill within 30 days. Multivariate survival analysis was used to follow patients to 
first adverse event or up to six years after index date to assess relative risk of 
adverse events. RESULTS: The study population included 1,348 patients treated 
with V+AP (female=52.6%, age=79.3 (± 6.9); history: liver disorder=5.9%, 
congestive heart failure=28.5%, peripheral arterial disease=32.2%) and 1,348 AP 
only patients (female=50.3%, age=79.1 (± 6.8); history: liver disorder=14.3%, 
congestive heart failure=27.9%, peripheral arterial disease=34.3%). Patients 
treated with AP only had a significantly lower risk of cerebrovascular disease 
(HR=0.65, 95% CI: 0.51-0.85, p=0.01) after controlling for potential confounders. 
Adding V did not increase risk of other outcomes evaluated. CONCLUSIONS: 
Clinical trials have failed to provide evidence of the efficacy of V as an adjunct 
therapy to AP to treat schizophrenia, but “off-label” prescribing of V+AP remains 
high. This study provides new evidence to inform prescribing practices in elderly 
patients with schizophrenia. The increased risk of stroke must be weighed 




ANTIPSYCHOTIC USE AND RISK OF PNEUMONIA IN ELDERLY NURSING HOME 
RESIDENTS: A PROPENSITY-MATCHED STUDY  
Chatterjee S, Aparasu RR, Chen H 
University of Houston, Houston, TX, USA  
OBJECTIVES: Antipsychotic medications are extensively used in nursing homes 
for management of behavioral and psychiatric disorders in the elderly. Prior 
research suggests that pneumonia is one of the common causes of 
antipsychotic-related mortality in this population. None of the studies compared 
typical and atypical antipsychotics with respect to pneumonia. This study 
examined the risk of pneumonia with use of typical versus atypical 
antipsychotics in dual eligible elderly nursing home residents. METHODS: The 
study involved a retrospective cohort design matched on propensity score using 
Medicare and Medicaid Analytical eXtract (MAX) data from four US states. The 
study population included elderly dual eligible (Medicaid and Medicare) nursing 
home residents (aged > 65 years) who initiated antipsychotics anytime during 
July 1, 2001 and December 31, 2003. The risk of pneumonia during the 6-month 
follow-up period was modeled using Cox proportional model and extended Cox 
hazard model stratified on matched pairs based on propensity scores, using 
atypical agents as the reference category. RESULTS: Analysis of Medicaid-
Medicare data revealed that there were 49,904 antipsychotic (46,293 atypical and 
3,611 typical) users in the unmatched cohort and 7,218 (3,609 atypical and 3,609 
typical) users in the matched cohort. The unadjusted rate of pneumonia was 
8.17% (295) for atypical users and 5.21% (188) for typical users. The results of Cox 
regression [average Hazards Ratio, HR, 1.24; 95% CI, 0.94-1.64] and extended 
regression [<50 days: HR, 1.17; 0.83-1.66 and 50-180 days: HR, 1.36; 0.87-2.14] 
suggest that, there was no difference in risk of pneumonia among typical  
and atypical users. CONCLUSIONS: The study found no differential risk  
of pneumonia among typical versus atypical antipsychotic use in dual eligible 
nursing home residents. Given the differential risk of mortality with typical  
and atypical use in nursing homes, more research is needed to evaluate  




RECURRENT STROKE RISK ASSOCIATED WITH ANTIDEPRESSANT USE IN  
POST-STROKE PATIENTS  
Wang MT, Chu CL 
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OBJECTIVES: Despite depression as the most frequent neuropsychiatric 
consequence of stroke, empirical safety evidence of antidepressant use in post-
stroke patients is absent. This study aimed to assess the risk of recurrent stroke 
by antidepressant use among patients with first-ever stroke. METHODS: A 
nested case-control study was performed among patients with first stroke 
analyzing data extracted from the National Health Insurance Research Database 
between 01/01/2000 and 12/31/2008. Cases identified as patients with recurrent 
stroke were individually matched with up to two randomly-selected controls by 
age, sex, and cohort entry date using an incidence density sampling approach. 
Conditional logistic regression was employed to estimate the recurrent stroke 
risk associated with selective serotonin reuptake inhibitors (SSRIs), tricyclic 
antidepressants (TCAs) and “other antidepressants”, as well as to assess the 
impact of dose, duration and recency of antidepressant therapy. RESULTS: The 
study cohort comprised 24,107 patients with first stroke, in which 4,415 cases 
were identified and matched to 8,294 randomly-selected controls. There was no 
statistically increased risk for any use of SSRIs (adjusted odds ratio [OR] = 0.99; 
95% CI, 0.78-1.26), TCAs (adjusted OR = 1.12; 95% CI, 0.96-1.30), or “other 
antidepressants” (adjusted OR = 1.10; 95% CI, 0.90-1.34). The insignificant risk for 
SSRIs remained regardless of varying dose, duration and recency of the therapy. 
However, short-term use of TCAs (≤ 30 days), discontinued TCA therapy in the 1-
30 days and 31-90 days preceding the index date was related to a 1.22-fold (95% 
CI, 1.01-1.49), 1.71-fold (95% CI, 1.18-2.48) and 1.50-fold (95% CI, 1.03-2.20) 
increased risk, respectively. The increased risk by use of “other antidepressants” 
was confined to short-term use (≤ 30 days; adjusted OR = 1.40; 95% CI, 1.07-1.81). 
CONCLUSIONS: Discontinued TCA therapy, short-term use of TCAs and “other 
antidepressants” all increase the recurrent stroke risk in post-stroke patients, 
which warrants clinical vigilance.  
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ECONOMIC BURDEN OF ANXIETY IN VETERAN PATIENTS IN THE UNITED 
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OBJECTIVES: To assess the clinical and treatment characteristics as well as 
economic burden of anxiety patients in the U.S. veteran population. METHODS: 
A retrospective analysis was performed using the Veterans Health 
Administration (VHA) Medical SAS Datasets from October 1, 2005 to May 31, 2012. 
All U.S. veteran beneficiaries diagnosed with anxiety were identified using 
International Classification of Disease 9th Revision Clinical Modification (ICD-9-
CM) diagnosis code 300.xx. Comorbid condition status was examined for the 12-
month baseline period before disease identification, and treatment patterns 
were examined for the period between the disease identification date and 60 
days after the identification date. Health care utilization and costs were 
measured in the 12-month follow-up period. RESULTS: A total of 687,325 
patients were diagnosed with anxiety. Common comorbidities included 
hypertension (n=165,086, 24.02%), depressive disorder (n=99,736, 14.51%), post-
traumatic stress disorder (n=92,514, 13.46%) and diabetes (n=89,041, 12.95%). The 
top treatments were simvastatin (n=139,001, 20.22%), citalopram hydrobromide 
(n=118,280, 17.21%), omeprazole (n=112,032, 16.30%), and lisinopril (n=103,489, 
15.06%). Other available treatments were trazodone, sertraline hydrochloride, 
lorazepam, hydrochlorothiazide and aspirin. The numbers of anxiety patients 
with inpatient, outpatient and pharmacy visits were 136,109 (19.80%), 686,307 
(99.85%) and 649,999 (94.57%), respectively, and related costs were $6,586 
(standard deviation [SD]=$32,770), $8,831 (SD=$12,369) and $1,576 (SD=$10,109). 
CONCLUSIONS: U.S. veterans diagnosed with anxiety frequently experienced 
comorbidities such as hypertension, depressive disorder, post-traumatic stress 
disorder, and diabetes in the 1-year baseline period. Future treatment regimen 
choices may need to address anxiety within the context of these comorbidities.  
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OBJECTIVES: To investigate the outcomes of patients with schizophrenia who 
lacked symptomatic control with conventional antipsychotics who were 
switched to olanzapine. METHODS: A post-hoc analysis was conducted on the 
China subgroup (n=475) of a multi-country, 12-month, prospective, non-
interventional observational study. Outcome measures included: Brief 
Psychiatric Rating Scale (BPRS), Clinical Global Impressions-Severity (CGI-S), 
Abnormal Involuntary Movements Scale (AIMS) and the brief WHO-Quality of 
Life Scale (WHO-QoL-BREF). Mixed models for repeated measures controlling for 
baseline scores, gender, age, baseline weight, and investigator were used to 
assess outcomes. RESULTS: Mean baseline CGI-S was 5.02 (95% C.I.: 4.94, 5.11). 
Most patients responded to olanzapine - 97% (95% C.I.: 94%, 98%) defined as a 
reduction in BPRS total score at endpoint by ≥30% relative to baseline. Significant 
improvements were observed in clinical status. LsMean change in BPRS total at 
month 12 from baseline was -33.3 (95% C.I.: -33.9, -32.8), and -3.4 for CGI-S (95% 
C.I.: -3.5, -3.3). Quality of life improved significantly for all domains of the WHO 
QoL-BREF. LsMean changes (improvements) from baseline to month 12 were: 
Physical 26.1(95% C.I.: 25.1, 27.2), Psychological 28.9 (95% C.I.: 27.6, 30.2), Social 
26.1 (95% C.I.: 24.5, 27.6) and Environment 24.3 (95% C.I.: 23.0, 25.6). Mean 
olanzapine dose at endpoint was 7.6mg (range 2.5, 25.0mg). AIMS score 
decreased from 3.9 to 0.3 (p<.0001) over the course of the study. Olanzapine 
treatment was associated with a mean weight gain of 4.2kg (95% C.I.:3.8, 4.6), and 
43% (95% C.I.: 38%, 48%) gained ≥7% of their baseline weight over 12 months. 
CONCLUSIONS: This post-hoc analysis suggests that for patients from mainland 
China with schizophrenia who are still symptomatic, despite previous treatment 
with conventional antipsychotics, switching to olanzapine may result in 
additional benefits in terms of further improvement in symptoms and quality of 
life, and a reduction in abnormal involuntary movements.  
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OBJECTIVES: The goal of this study was to evaluate the efficacy and safety of 
armodafinil as an adjunctive therapy for major depression associated with 
bipolar I disorder. METHODS: Patients 18-65 years of age with bipolar I disorder 
currently experiencing a major depressive episode while taking 1 or 2 mood 
stabilizer(s) and/or second-generation antipsychotics were randomized. The 
primary outcome was the mean change from baseline to week 8 in the 30-item 
Inventory of Depressive Symptomatology–Clinician-rated (IDS-C30) total score. 
RESULTS: 433 patients were randomized (n=199 placebo, n=201 armodafinil 150 
mg, n=33 armodafinil 200 mg). Randomization to the 200 mg armodafinil group 
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was discontinued early; only safety results from this group are presented. For the 
armodafinil 150 mg group compared with placebo, there was a significantly 
greater decrease in LS mean (SEM) IDS-C30 total score (−21.7 [1.11] vs −17.9 [1.10]; 
P=0.0097) at week 8 and the percentage of IDS-C30 responders (≥50% decrease 
from baseline) was significantly greater at week 8 (55% vs 39%; P=0.0084) and 
final visit (46% vs 34%; P=0.0147). The most common AEs were headache (9.6% vs 
10.1%), diarrhea (8.6% vs 6.5%), and nausea (5.6% vs 4.5%) for the armodafinil 150 
mg and placebo groups, respectively, and headache (21.9%), insomnia (12.5%), 
and nausea (9.4%) for the armodafinil 200 mg group. At final visit, 5% (9/183) of 
patients in the placebo group, 2% (3/186) of the 150 mg group, and 4% (1/28) of 
the 200 mg group had potentially clinically significant (≥7%) weight gain from 
baseline. CONCLUSIONS: Armodafinil 150 mg significantly improved depressive 
symptoms compared with placebo in patients with a major depressive episode 
associated with bipolar I disorder when given as adjunctive treatment to mood 
stabilizers. Safety data indicate that adjunctive armodafinil 150 mg was generally 
well tolerated.  
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PATIENTS FOLLOWING LONG-TERM TREATMENT WITH LEVOMILNACIPRAN SR  
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OBJECTIVES: Levomilnacipran (1S, 2R-milnacipran) is a potent and selective 
serotonin and norepinephrine reuptake inhibitor (SNRI) with approximately 2-
fold greater potency for reuptake inhibition of norepinephrine than serotonin. A 
sustained release (SR) formulation was developed for once-daily dosing. 
Levomilnacipran SR is in late-stage clinical development for major depressive 
disorder (MDD). Analyses were conducted to evaluate the long-term benefits of 
levomilnacipran SR treatment on the functional health and well-being of adult 
MDD patients as measured by the SF-36v2 Health Survey. METHODS: Patients 
with MDD who completed 1 of 3 placebo-controlled studies (lead-in studies) were 
eligible to participate in this open-label extension study (NCT01034267), 
consisting of a 48-week open-label treatment period with levomilnacipran SR 40-
120 mg/d. The mean change from baseline (start of lead-in study) to end of study 
for each individual health domain [Physical Functioning (PF), Role Physical (RP), 
Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role 
Emotional (RE), Mental Health (MH)], and the Physical (PCS) and Mental (MCS) 
Component Summary scores were analyzed using Last-Observation-Carry-
Forward (LOCF) and Observed Cases (OC). RESULTS: A total of 811 patients in the 
intent-to-treat population had a baseline SF-36 evaluation; 758 (LOCF) and 378 
(OC) patients completed 48-weeks of treatment in the extension study. With the 
exception of PCS, which had baseline scores (mean±SD: 50.60±10.91) within the 
normal range, improvement from baseline was seen for the MCS (baseline: 
18.97±9.22) and all individual health domains, which was maintained over the 
course of the study period. Changes from baseline at week-48 were: MCS (LOCF: 
22.04±16.95, OC: 26.53±15.42); PF (3.96±10.26, 5.48±10.53); RP (6.29±13.21, 
8.45±13.01); BP (5.17±11.82, 7.01±11.57); GH (6.16±9.39, 8.01±9.49); VT (14.84±13.28, 
18.51±12.76); SF (16.55±14.70, 20.24±13.52); RE (17.47±15.39, 20.87±14.32); MH 
(18.10±14.76, 22.19±13.62). CONCLUSIONS: Long-term treatment with 
levomilnacipran SR in patients with MDD resulted in sustained improvement in 
functional health and well-being as measured by the SF-36.  
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OBJECTIVES: Describe changes in Clinical Global Impressions Severity (CGI-S) 
scores for adults with schizophrenia and/or schizoaffective disorder recently 
initiated on a new oral atypical antipsychotic (OA) or paliperidone palmitate (PP). 
METHODS: Adults with schizophrenia and/or schizoaffective disorder captured 
in the Duke Mindlinc EMR system (1/1/2010- 12/31/2011), with >90 days of 
treatment with the index therapy (first PP or OA prescription following a switch), 
CGI-S score at baseline, 1 or more CGI-S scores over 90 days post-index, and data 
activity 180 days prior to and 270 days post-index (proxy for eligibility). CGI-S 
scores were evaluated in two 90-day windows prior to and three 90-day windows 
post-index date. Changes in CGI-S over time were assessed using Cochran-
Mantel-Haenszel tests and generalized estimating equation models. RESULTS: A 
total of 980 patients (63 PP/917 OA) met all criteria. Patients were of similar mean 
age (PP 41+SD 11.5; OA 39+11.6; p=0.2011) and gender (female: PP 48%; OA 49%; 
p=0.8626). PP patients showed significantly greater CGI-S at baseline (PP 4.8+1.0); 
OA 4.3+1.1; p=0.0011), more comorbidities, and a higher percentage hospitalized 
180 days prior to index (PP 22%; OA 11%; p=0.0075). While changes in CGI-S over 
time (Time -2, Time -1, Baseline, Time 1, Time 2, and Time 3) were modest, CGI-S 
Scores for PP patients (PP- 4.5+1.4, 4.6+1.5, 4.8+1.0, 4.6+1.0, 4.4+1.1, 4.2+1.3) 
showed greater improvement over time versus OA patients (OA- 4.1+1.2, 4.2+1.2, 
4.3+1.1, 4.1+1.1, 4.2+1.1, 4.1+1.2). CONCLUSIONS: In this ‘real-world’ evaluation of 
CGI-S scores using EMR data, PP patients showed an improvement over time 
while OA patients remained relatively flat.  
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OBJECTIVES: Identify clinical features, findings on CT and MRI of the brain and 
the determination of herpes virus 1, 2 and 6 in cerebrospinal fluid (CSF) by 
Western Blot test and PCR. METHODS: Was performed on all patients admitted 
to the Department of Neurology Specialty Hospital National Medical Center 
Century XXI, IMSS, in the period of March 2009 on the date 2011 that date who 
had symptoms and signs related acute herpes encephalitis. A clinical history and 
complete neurological examination were realized. Was obtained by lumbar 
puncture for cytochemical cerebrospinal fluid, cytological, culture, Herpes 
antigens 1, 2, 6 and precipitated DNA was obtained by PCR for the determination. 
RESULTS: Twelve patients positive for herpes virus 1, 2 and 6. The most 
outstanding neurological characteristics of these patients were: headache in 10 
of the 12 patients, (83%) and confuse state in 10 of the 12 patients, (83%), in the 
CSF, was identified lymphocytic pleocytosis in all the patients in a range of 7 a 
500 cells an average value of 110, high protein in all patients from 38 to 322 mg/dl 
range an average 124.4. The main findings in CT and RM were bilateral 
hypodensity, multifocal extratemporal injury and ventricular dilatation and 
magnetic resonance signal change in temporal or extratemporal regions with 
enhancement in lesions, all patients were treated with acliclovir. At follow-up at 
6 months: No reported deaths and major sequelae secondary symptomatic 
epilepsy and mild cognitive impaire CONCLUSIONS: The herpes virus positive 
patients 1,2 and 6 show an early diagnosis of encephalitis and remains an urgent 
neurological identify characteristics and initiate early comprehensive 
management including acyclovir to reduce morbidity and mortality in this 
patient group.  
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OBJECTIVES: Despite buprenorphine’s promise as a novel therapy for opioid 
dependence, little is known about its clinical adoption. We characterized trends 
in ambulatory use and sales of buprenorphine and methadone in the United 
States. METHODS: Cross-sectional analyses of buprenorphine and methadone 
utilization and sales using data from the IMS Health National Disease and 
Therapeutic Index, a nationally representative survey of ambulatory care (1997-
2012), the IMS Health National Prescription Audit, reflecting retail, long-term 
care and mail-order pharmacy sales (2007-2011), and the IMS Health National 
Sales Perspective, capturing distribution of products from manufacturers to 
suppliers (2007-2011). RESULTS: Between 2003 and 2011, there was a sharp 
increase in buprenorphine ambulatory treatment visits, with an annual rate of 
increase of approximately 37%, reaching nearly 2 million treatment visits during 
2011. During this period, the proportion of buprenorphine treatment visits 
accounted for by psychiatrists decreased from 92% to 37%. Two-thirds of 2011 
treatment visits were for individuals 20-39 years of age, while 91% of these visits 
were for drug abuse or dependence and 90% involved the use of combination 
buprenorphine/naloxone (Suboxone) rather than other buprenorphine products. 
Between January 2007 and December 2011, there were modest increases in retail 
pharmacy prescriptions for methadone, from approximately 325 to 375 thousand 
monthly prescriptions. By contrast, buprenorphine sales increased by an average 
of 40% annually during this period, from approximately 0.5 million during the 
first quarter of 2007 to 2.7 million during the last quarter of 2011. Despite these 
increases, methadone sales from manufacturers to distributors remained 
generally steady and four-fold greater than buprenorphine sales. CONCLUSIONS: 
Since 2003, there has been a large increase in buprenorphine utilization. While 
the impact of increases in buprenorphine use on the epidemic of prescription 
opioid abuse remains to be examined, the increases reflect a substantial shift in 
the landscape of opioid dependence treatment.  
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OBJECTIVES: Stimulants are recommended first-line treatments for attention 
deficit hyperactivity disorder (ADHD), but increased use of other psychotropic 
medications such as antipsychotics and antidepressants has been reported. 
However, recent nationally representative estimates are lacking. This study 
examined the recent trends in use of psychotropic medications among children 
with ADHD in the US. METHODS: This retrospective study utilized the data from 
Medical Expenditure Panel Survey for the years 2002-2010. Trends in use of 
psychotropic medications (stimulants, antipsychotics, antidepressants, 
anxiolytics/sedatives/hypnotics, mood stabilizers and clonidine) were examined. 
Unadjusted logistic regressions were conducted to assess the significance of 
trends in medication use over time. Logistic regressions were conducted to 
identify the socio demographic characteristics and comorbid psychotic disorders 
(schizophrenia, bipolar disorder, depression/anxiety, autistic disorders) 
associated with the use of each psychotropic medication class. RESULTS: Use of 
stimulants was most common during the study period, which increased sharply 
from 43.0% in 2002 to 80.8% in 2006 but decrease afterwards to 62.2% in 2010. Use 
of antidepressants accounted for 10.4% and with no statistical significant trend 
over time annually. Antipsychotics was used for 9.3% of ADHD children annually 
but increased in recent years from 7.2% in 2002-2004 to 11.3% in 2008-2010 (OR: 
1.6, 95% CI: 1.1-2.6). Having schizophrenia (OR 26.6: CI 2.95-239.6) or bipolar 
